Join
Live feed
·
PRReleasevia Quantisnow
Rhythm Pharmaceuticals Inc. logo

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

ByQuantisnow·Wall Street's wire, on your screen.
RYTM· Rhythm Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RYTM (Rhythm Pharmaceuticals Inc.) and more on Quantisnow.